

Supplementary Materials: Comprehensive Genomic Characterization of Fifteen Early-Onset Lynch-Like Syndrome Colorectal Cancers

Mariano Golubicki, Marcos Díaz-Gay, Laia Bonjoch, Sebastià Franch-Expósito, Jenifer Muñoz, Miriam Cuatrecasas, Teresa Ocaña, Soledad Iseas, Guillermo Mendez, Marcela Carballido, Juan Robbio, Daniel Cisterna, Enrique Roca, Antoni Castells, Francesc Balaguer, Sergi Castellví-Bel and Marina Antelo




Figure S1. Additional most common somatic mutated genes in colorectal cancer.




Figure S2. TMB comparison between biallelic somatic inactivations patients and with those who are not biallelic inactivated.





Figure S3. Single Base Substitution and InDels De novo mutational signatures.

Table S1. CRC Patients from CBioPortal with MSH3 truncating variants and no other MMR alterations showing microsatellite instability.

SAMPLE ID	STUDY ORIGIN IN CBIOPORTAL	MSH3 VARIANTS	ANNOTATION	MSI STATUS	MUTATION COUNT
11CO033	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	K383Rfs*32	OncoKB: Likely Oncogenic, level NA;QVIC: NA;MyCancerGenome: not present;CancerHotspot: no;3DHotspot: no	MSI	1810
11CO036	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	S1022*	OncoKB: Likely Oncogenic, level NA;QVIC: NA;MyCancerGenome: not present;CancerHotspot: no;3DHotspot: no	MSI	1805
11CO061	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	K383Rfs*32	OncoKB: Likely Oncogenic, level NA;QVIC: NA;MyCancerGenome: not present;CancerHotspot: no;3DHotspot: no	MSI	736
TCGA-AA-A00A	Colorectal Adenocarcinoma (TCGA, Nature 2012)	K381Gfs*20	OncoKB: Likely Oncogenic, level NA;QVIC: NA;MyCancerGenome: not present;CancerHotspot: no;3DHotspot: no	MSI	324
TCGA-AA-A01Q	Colorectal Adenocarcinoma (TCGA, Nature 2012)	K381Gfs*20	OncoKB: Likely Oncogenic, level NA;QVIC: NA;MyCancerGenome: not present;CancerHotspot: no;3DHotspot: no	MSI	595
TCGA-AA-3492	Colorectal Adenocarcinoma (TCGA, PanCancer Atlas)	N861Mfs*6	OncoKB: Likely Oncogenic, level NA;QVIC: NA;MyCancerGenome: not present;CancerHotspot: no;3DHotspot: no	MSI	no data
TCGA-AA-3663	Colorectal Adenocarcinoma (TCGA, PanCancer Atlas)	N1020Ifs*40	OncoKB: Likely Oncogenic, level NA;QVIC: NA;MyCancerGenome: not present;CancerHotspot: no;3DHotspot: no	no data	1937
coadread_dfci_2016_60	Colorectal Adenocarcinoma (DFCI, Cell Reports 2016)	K383Rfs*32	OncoKB: Likely Oncogenic, level NA;QVIC: NA;MyCancerGenome: not present;CancerHotspot: no;3DHotspot: no	MSI	1257
coadread_dfci_2016_116	Colorectal Adenocarcinoma (DFCI, Cell Reports 2016)	Q1058*	OncoKB: Likely Oncogenic, level NA;QVIC: NA;MyCancerGenome: not present;CancerHotspot: no;3DHotspot: no	MSS	4474
coadread_dfci_2016_261	Colorectal Adenocarcinoma (DFCI, Cell Reports 2016)	K383Rfs*32	OncoKB: Likely Oncogenic, level NA;QVIC: NA;MyCancerGenome: not present;CancerHotspot: no;3DHotspot: no	MSI	1062
coadread_dfci_2016_407	Colorectal Adenocarcinoma (DFCI, Cell Reports 2016)	K383Rfs*32	OncoKB: Likely Oncogenic, level NA;QVIC: NA;MyCancerGenome: not present;CancerHotspot: no;3DHotspot: no	MSI	535
coadread_dfci_2016_1212	Colorectal Adenocarcinoma (DFCI, Cell Reports 2016)	K383Rfs*32	OncoKB: Likely Oncogenic, level NA;QVIC: NA;MyCancerGenome: not present;CancerHotspot: no;3DHotspot: no	MSI	1739
coadread_dfci_2016_2227	Colorectal Adenocarcinoma (DFCI, Cell Reports 2016)	X303_splice	OncoKB: Likely Oncogenic, level NA;QVIC: NA;MyCancerGenome: not present;CancerHotspot: no;3DHotspot: no	MSI	588

Table S2. Comparative studies showing clinical and molecular differences in published cohorts.

Author	year	Number of CRC LLS patients	Mean age at CRC diagnosis (years old)	Patients with double somatic alterations in MMR genes (%) of total cohort	Number of patients with CRC≤40	Mean age at CRC diagnosis (years old)	Patients with Double somatic alterations in MMR genes (%) of patients with CRC≤40
Sourouille	2013	17	54	24%	3	28	0%
Haraldsottir	2014	15	54	93%	4	34	100%
Mensenkamp	2014	23	47	48%	5	33	60%
Geurts-Giele W	2014	33	55	51%	5	35	0%
Porkka	2019	14	65	79%	1	38	100%
Xicola	2019	11	63	54%	0	-	-
Golubicki	2020	15	30	33%	15	30	33%

Table S3. Additional quality sequencing data from Table 2 variants.

Sample ID	Gene name	HGVS,c	HGVS,p	Variant impact	TumorAD	TumorDP	Tumor AF
Biallelic somatic variants							
LLS02	<i>MSH3</i>	c.423C>A	p.Cys141*	stop_gained	4,6	10	0,6
LLS09	<i>MSH3</i>	c.1148delA	p.Lys383fs	frameshift_variant	7,6	13	0,4615
LLS10	<i>MSH3</i>	c.1148delA	p.Lys383fs	frameshift_variant	28,43	71	0,6056
LLS10	<i>POLD1</i>	c.583C>T	p.Arg195*	stop_gained	119,68	187	0,3636
LLS10	<i>POLD1</i>	c.2959delG	p.Asp987fs	frameshift_variant	85,56	141	0,3972
LLS17	<i>MLH1</i>	c.129dupA	p.Ser44fs	frameshift_variant	25,7	32	0,2188
LLS17	<i>MLH1</i>	c.1831delA	p.Ile611fs	frameshift_variant	52,26	78	0,3333
LLS18	<i>MSH2</i>	c.2251G>T	p.Gly751*	stop_gained	87,15	102	0,1471
LLS18	<i>MSH2</i>	c.2634+1G>A	-	splice_variant	73,17	90	0,1889
LLS21	<i>MLH1</i>	c.199G>A	p.Gly67Arg	missense_variant	129,2	149	0,1342
LLS21	<i>MLH1</i>	c.602delT	p.Val201fs	frameshift_variant	134,43	177	0,2429
LLS5159	<i>POLD1</i>	c.1562G>A	p.Arg521Gln	missense_variant	80,23	103	0,2233
LLS5159	<i>POLD1</i>	c.3047G>A	p.Arg1016His	missense_variant	57,21	78	0,2692
LLS9045	<i>MLH3</i>	c.3694C>T	p.Arg1232Cys	missense_variant	55,22	77	0,2857
LLS9045	<i>MLH3</i>	c.1924T>C	p.Phe642Leu	missense_variant	37,32	69	0,4638
LLS9045	<i>MLH1</i>	c.588delA	p.Lys196fs	frameshift_variant	25,7	32	0,2188
LLS9045	<i>MLH1</i>	c.1489delC	p.Arg497fs	frameshift_variant	119,32	151	0,2119
LLS9049	<i>POLD1</i>	c.2959delG	p.Asp987fs	frameshift_variant	50,22	72	0,3056
Monoallelic somatic variants							
LLS09	<i>MSH6</i>	c.3552G>A	p.Met1184Ile	missense_variant	19,8	27	0,2963
LLS10	<i>MSH6</i>	c.2875C>T	p.Arg959Cys	missense_variant	76,4	116	0,3448
LLS10	<i>POLE</i>	c.2091delC	p.Leu698fs	frameshift_variant	88,33	121	0,2727
LLS18	<i>MSH6</i>	c.3261dupC	p.Phe1088fs	frameshift_variant	324,47	371	0,1267
LLS19	<i>MSH2</i>	c.1225C>T	p.Gln409*	stop_gained	63,12	75	0,16
LLS19	<i>MSH6</i>	c.1993G>A	p.Glu665Lys	missense_variant	108,15	123	0,122
LLS21	<i>MSH3</i>	c.3356T>C	p.Leu1119Pro	missense_variant	30,5	35	0,1429
LLS21	<i>PMS2</i>	c.1239delA	p.Asp414fs	frameshift_variant	64,16	80	0,2
LLS21	<i>POLE</i>	c.1060A>G	p.Thr354Ala	missense_variant	49,12	61	0,1967
LLS9045	<i>MUTYH</i>	c.724C>T	p.Arg242Cys	missense_variant	58,33	91	0,3626
LLS9045	<i>POLD1</i>	c.735G>T	p.Glu245Asp	missense_variant	73,27	100	0,27
LLS9049	<i>MUTYH</i>	c.544C>T	p.Arg182Trp	missense_variant	99,15	114	0,1316
LLS9049	<i>MSH3</i>	c.433G>T	p.Ala145Ser	missense_variant	51,9	60	0,15
LLS9049	<i>POLE</i>	c.3176G>A	p.Arg1059His	missense_variant	97,24	121	0,1983

Table S4. Insight database classification from somatic MMR variants in Table 2.

InSight Classification for MMR variants				
Biallelic Somatic Variants				
Patient ID	Gene Name	HGVS.c	HGVS.p	InSight Classification
LLS17	<i>MLH1</i>	c.129dupA	p.Ser44fs	not present
LLS17	<i>MLH1</i>	c.1831delA	p.Ile611fs	Class 5: Pathogenic
LLS18	<i>MSH2</i>	c.2251G>T	p.Gly751*	not present
LLS18	<i>MSH2</i>	c.2634+1G>T	-	Class 4: Likely Pathogenic
LLS21	<i>MLH1</i>	c.199G>A	p.Gly67Arg	Class 5: Pathogenic
LLS21	<i>MLH1</i>	c.602delT	p.Val201fs	not present
LLS9045	<i>MLH1</i>	c.588delA	p.Lys196fs	Class 5: Pathogenic
LLS9045	<i>MLH1</i>	1849delC	p.Arg497fs	not present
Monoallelic Somatic Variants				
Patient ID	Gene Name	HGVS.c	HGVS.p	InSight Classification
LLS09	<i>MSH6</i>	c.3552G>A	p.Met1184Ile	not present
LLS10	<i>MSH6</i>	c.2875C>T	p.Arg959Cys	not present
LLS18	<i>MSH6</i>	c.3261dupC	p.Phe1088fs	Class 5: Pathogenic
LLS19	<i>MSH2</i>	c.1225C>T	p.Gln409*	not present
LLS19	<i>MSH6</i>	c.1993G>A	p.Glu665Lys	not present
LLS21	<i>PMS2</i>	c.1239delA	p.Asp414fs	not present

Table S5. ACMG classification criteria from Table 2 somatic variants.

Biallelic somatic variants								
Sample ID	Gene name	HGVS.c	HGVS.p	Variant impact	gnomAD	ClinVar	COSMIC	ACMG classification criteria
LLS02	<i>MSH3</i>	c.423C>A	p.Cys141*	stop_gained	not present	not present	not present	Pathogenic (PVS1; PMS2; PP3)
LLS09	<i>MSH3</i>	c.1148delA	p.Lys383fs	frameshift_variant	1,64E-05	Pathogenic	COSM1438888	Pathogenic (PVS1; PS3; PP3; PP5)
LLS10	<i>MSH3</i>	c.1148delA	p.Lys383fs	frameshift_variant	1,64E-05	Pathogenic	COSM1438888	Pathogenic (PVS1; PS3; PP3; PP5)
LLS10	<i>POLD1</i>	c.583C>T	p.Arg195*	stop_gained	0,0000647	Conflicting	not present	Benign (PVS1; PP3; BS1; BS2)
LLS10	<i>POLD1</i>	c.2959delG	p.Asp987fs	frameshift_variant	0,000057209	not present	COSM3686158	Likely Pathogenic (PVS1; PM2)
LLS17	<i>MLH1</i>	c.129dupA	p.Ser44fs	frameshift_variant	not present	Pathogenic	not present	Pathogenic (PVS1; PM2; PP3; PP5)
LLS17	<i>MLH1</i>	c.1831delA	p.Ile611fs	frameshift_variant	not present	not present	not present	Pathogenic (PVS1; PM2; PP3)
LLS18	<i>MSH2</i>	c.2251G>T	p.Gly751*	stop_gained	not present	not present	not present	Pathogenic (PVS1; PM2; PP3)
LLS18	<i>MSH2</i>	c.2634+1G>A	-	splice_variant	not present	Likely_pathogenic	not present	Pathogenic (PVS1; PM2; PP3; PP5)
LLS21	<i>MLH1</i>	c.199G>A	p.Gly67Arg	missense_variant	not present	Pathogenic	COSM1422567	Pathogenic (PS1; PM1; PM2; PM5; PP2; PP3; PP5)
LLS21	<i>MLH1</i>	c.602delT	p.Val201fs	frameshift_variant	not present	not present	not present	Likely Pathogenic (PVS1; PM2)
LLS159	<i>POLD1</i>	c.1562G>A	p.Arg521Gln	missense_variant	0,000126296	VUS	not present	Benign (PP3; BS1; BS2; BP1)
LLS159	<i>POLD1</i>	c.3047G>A	p.Arg1016His	missense_variant	not present	VUS	COSM7587416	VUS (PM2; PP3; BP1)
LLS9045	<i>MLH3</i>	c.3694C>T	p.Arg1232Cys	missense_variant	3,25E-05	VUS	not present	VUS (PP3; BP1)
LLS9045	<i>MLH3</i>	c.1924T>C	p.Phe642Leu	missense_variant	not present	not present	not present	Likely Benign (PM2; BP1; BP4)
LLS9045	<i>MLH1</i>	c.588delA	p.Lys196fs	frameshift_variant	4,06E-06	Pathogenic	not present	Pathogenic (PVS1; PM2; PP3; PP5)
LLS9045	<i>MLH1</i>	c.1489delC	p.Arg497fs	frameshift_variant	4,06E-06	not present	COSM1422596	Pathogenic (PVS1; PM2; PP3; PP5)
LLS9049	<i>POLD1</i>	c.2959delG	p.Asp987fs	frameshift_variant	0,000057209	not present	COSM3686158	Likely Pathogenic (PVS1; PM2)
Monoallelic somatic variants								
Sample ID	Gene name	HGVS.c	HGVS.p	Variant impact	gnomAD	ClinVar	COSMIC	ACMG classification criteria
LLS09	<i>MSH6</i>	c.3552G>A	p.Met1184Ile	missense_variant	4,07E-06	not present	not present	VUS (PM2; PP3)
LLS10	<i>MSH6</i>	c.2875C>T	p.Arg959Cys	missense_variant	1,22E-05	VUS	not present	VUS (PM2; PP3)
LLS10	<i>POLE</i>	c.2091delC	p.Leu698fs	frameshift_variant	8,21E-06	VUS	COSM4612998	Pathogenic (PVS1; PM2; PP3)
LLS18	<i>MSH6</i>	c.3261dupC	p.Phe1088fs	frameshift_variant	0,00003449	Pathogenic	COSM13394	Pathogenic (PVS1; PM2; PP3; PP5)
LLS19	<i>MSH2</i>	c.1225C>T	p.Gln409*	stop_gained	not present	Pathogenic	COSM7508782	Pathogenic (PVS1; PM2; PP3; PP5)
LLS19	<i>MSH6</i>	c.1993G>A	p.Glu665Lys	missense_variant	4,07E-06	not present	not present	VUS (PM2; PP3)
LLS21	<i>MSH3</i>	c.3356T>C	p.Leu119Pro	missense_variant	not present	not present	not present	VUS (PM2; PP3)
LLS21	<i>PMS2</i>	c.1239delA	p.Asp414fs	frameshift_variant	not present	not present	COSM150905	Pathogenic (PVS1; PM2; PP3)
LLS21	<i>POLE</i>	c.1060A>G	p.Thr354Ala	missense_variant	not present	not present	not present	Likely Benign (PM2; BP1; BP4)
LLS9045	<i>MUTYH</i>	c.724C>T	p.Arg242Cys	missense_variant	5,30E-05	Pathogenic	COSM6954579	Pathogenic (PM1; PM2; PM5; PP2; PP3; PP5)
LLS9045	<i>POLD1</i>	c.735G>T	p.Glu245Asp	missense_variant	not present	not present	not present	Likely Benign (PM2; BP1; BP4)
LLS9049	<i>MUTYH</i>	c.544C>T	p.Arg182Trp	missense_variant	1,22E-05	not present	COSM6922477	Pathogenic (PM1; PM2; PM5; PP2; PP3; PP5)
LLS9049	<i>MSH3</i>	c.433G>T	p.Ala145Ser	missense_variant	not present	VUS	not present	VUS (PM2; BP4)
LLS9049	<i>POLE</i>	c.3176G>A	p.Arg1059His	missense_variant	1,22E-05	not present	COSM6965827	VUS (PM2; PP3; BP1)